Peter Holzer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Peter Holzer has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
E. Painsipp
Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria
6 shared publicationsEvelin Painsipp
Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Universitätsplatz 4, A-8010 Graz, Austria
4 shared publicationsT. Wultsch
Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria
4 shared publicationsA. Shahbazian
Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria
2 shared publicationsC.K. Thoeringer
Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria
2 shared publicationsE. Bock
Institute of Cell Biology, Histology and Embryology, Centre of Molecular Medicine, Medical University of Graz, Graz, Austria
2 shared publications
Latest Publications
- 1 December 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 155 (8) , 1145-1162
The pharmacological challenge to tame the transient receptor potential vanilloid‐1 (TRPV1) nocisensor
The transient receptor potential vanilloid‐1 (TRPV1) cation channel is a receptor that is activated by heat (>42 °C), acidosis (pHBritish Journal of Pharmacology(2008)155, 1145–1162; doi:fn2; published online 22 September 2008
- 1 December 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 155 (8) , 1145-1162
The pharmacological challenge to tame the transient receptor potential vanilloid‐1 (TRPV1) nocisensor
The transient receptor potential vanilloid‐1 (TRPV1) cation channel is a receptor that is activated by heat (>42 °C), acidosis (pHBritish Journal of Pharmacology(2008)155, 1145–1162; doi:fn2; published online 22 September 2008
- 1 August 2008
- Vol. 12, 119-27
New approaches to the treatment of opioid-induced constipation.
Opiates are indispensable for the treatment of moderate to severe pain. The gastrointestinal tract is one of the major victims of the undesired effects of opiates, because the enteric nervous system expresses all major subtypes of opioid receptors. As a result, propulsive motility and secretory processes in the gut are inhibited by opioid analgesics, and the ensuing constipation is one of the most frequent and troublesome adverse reactions. Many treatments involving laxatives, prokinetic drugs and opioid-sparing regimens have been explored to circumvent opioid-induced bowel dysfunction, but the outcome has in general been unsatisfactory. Specific antagonism of peripheral opioid receptors offers a more rational approach to the management of the adverse actions of opioid analgesics in the gut. This goal is currently addressed by the use of opioid receptor antagonists with limited absorption such as oral naloxone and by the development of peripherally restricted opioid receptor antagonists such as methylnaltrexone and alvimopan. These investigational drugs hold considerable promise in preventing constipation due to opiate treatment, whereas the analgesic action of opiates remains unabated. Postoperative ileus associated with opioid-induced postsurgical pain control is likewise ameliorated by the compounds. With this proof of concept, several phase III studies are under way to define optimal dosage, dosing regimen as well as long-term efficacy and safety of methylnaltrexone and alvimopan. In addition, there is preliminary evidence that these peripherally restricted opioid receptor antagonists may act as prokinetic drugs in their own right.
- 1 August 2008
- Vol. 12, 119-27
New approaches to the treatment of opioid-induced constipation.
Opiates are indispensable for the treatment of moderate to severe pain. The gastrointestinal tract is one of the major victims of the undesired effects of opiates, because the enteric nervous system expresses all major subtypes of opioid receptors. As a result, propulsive motility and secretory processes in the gut are inhibited by opioid analgesics, and the ensuing constipation is one of the most frequent and troublesome adverse reactions. Many treatments involving laxatives, prokinetic drugs and opioid-sparing regimens have been explored to circumvent opioid-induced bowel dysfunction, but the outcome has in general been unsatisfactory. Specific antagonism of peripheral opioid receptors offers a more rational approach to the management of the adverse actions of opioid analgesics in the gut. This goal is currently addressed by the use of opioid receptor antagonists with limited absorption such as oral naloxone and by the development of peripherally restricted opioid receptor antagonists such as methylnaltrexone and alvimopan. These investigational drugs hold considerable promise in preventing constipation due to opiate treatment, whereas the analgesic action of opiates remains unabated. Postoperative ileus associated with opioid-induced postsurgical pain control is likewise ameliorated by the compounds. With this proof of concept, several phase III studies are under way to define optimal dosage, dosing regimen as well as long-term efficacy and safety of methylnaltrexone and alvimopan. In addition, there is preliminary evidence that these peripherally restricted opioid receptor antagonists may act as prokinetic drugs in their own right.
- Open Access
- 9 July 2008
- Published by Wiley in Genes, Brain and Behavior
- Vol. 7 (5) , 532-542
Reduced anxiety‐like and depression‐related behavior in neuropeptide Y Y4 receptor knockout mice
Neuropeptide Y (NPY) acting through Y1 receptors reduces anxiety‐ and depression‐like behavior in rodents, whereas Y2 receptor stimulation has the opposite effect. This study addressed the implication of Y4 receptors in emotional behavior by comparing female germ line Y4 knockout (Y4−/−) mice with control and germ line Y2−/− animals. Anxiety‐ and depression‐like behavior was assessed with the open field (OF), elevated plus maze (EPM), stress‐induced hyperthermia (SIH) and tail suspension tests (TST), respectively. Learning and memory were evaluated with the object recognition test (ORT). In the OF and EPM, both Y4−/− and Y2−/− mice exhibited reduced anxiety‐related behavior and enhanced locomotor activity relative to control animals. Locomotor activity in a familiar environment was unchanged in Y4−/− but reduced in Y2−/− mice. The basal rectal temperature exhibited diurnal and genotype‐related alterations. Control mice had temperature minima at noon and midnight, whereas Y4−/− and Y2−/− mice displayed only one temperature minimum at noon. The magnitude of SIH was related to time of the day and genotype in a complex manner. In the TST, the duration of immobility was significantly shorter in Y4−/− and Y2−/− mice than in controls. Object memory 6 h after initial exposure to the ORT was impaired in Y2−/− but not in Y4−/− mice, relative to control mice. These results show that genetic deletion of Y4 receptors, like that of Y2 receptors, reduces anxiety‐like and depression‐related behavior. Unlike Y2 receptor knockout, Y4 receptor knockout does not impair object memory. We propose that Y4 receptors play an important role in the regulation of behavioral homeostasis.
- 9 July 2008
- Published by Wiley in Genes, Brain and Behavior
- Vol. 7 (5) , 532-542
Open AccessReduced anxiety‐like and depression‐related behavior in neuropeptide Y Y4 receptor knockout mice
Neuropeptide Y (NPY) acting through Y1 receptors reduces anxiety‐ and depression‐like behavior in rodents, whereas Y2 receptor stimulation has the opposite effect. This study addressed the implication of Y4 receptors in emotional behavior by comparing female germ line Y4 knockout (Y4−/−) mice with control and germ line Y2−/− animals. Anxiety‐ and depression‐like behavior was assessed with the open field (OF), elevated plus maze (EPM), stress‐induced hyperthermia (SIH) and tail suspension tests (TST), respectively. Learning and memory were evaluated with the object recognition test (ORT). In the OF and EPM, both Y4−/− and Y2−/− mice exhibited reduced anxiety‐related behavior and enhanced locomotor activity relative to control animals. Locomotor activity in a familiar environment was unchanged in Y4−/− but reduced in Y2−/− mice. The basal rectal temperature exhibited diurnal and genotype‐related alterations. Control mice had temperature minima at noon and midnight, whereas Y4−/− and Y2−/− mice displayed only one temperature minimum at noon. The magnitude of SIH was related to time of the day and genotype in a complex manner. In the TST, the duration of immobility was significantly shorter in Y4−/− and Y2−/− mice than in controls. Object memory 6 h after initial exposure to the ORT was impaired in Y2−/− but not in Y4−/− mice, relative to control mice. These results show that genetic deletion of Y4 receptors, like that of Y2 receptors, reduces anxiety‐like and depression‐related behavior. Unlike Y2 receptor knockout, Y4 receptor knockout does not impair object memory. We propose that Y4 receptors play an important role in the regulation of behavioral homeostasis.
- 1 July 2008
- Published by Elsevier in Neuropharmacology
- Vol. 55 (1) , 117-126
Implication of neuropeptide-Y Y2 receptors in the effects of immune stress on emotional, locomotor and social behavior of mice
- 1 July 2008
- Published by Elsevier in Neuropharmacology
- Vol. 55 (1) , 117-126
Implication of neuropeptide-Y Y2 receptors in the effects of immune stress on emotional, locomotor and social behavior of mice
TRPV1: a new target for treatment of visceral pain in IBS?
What are the mechanisms whereby we sense spices, and what do they have to do with functional disorders of the gastrointestinal (GI) tract? Even one decade ago, nobody could envisage that a large family of closely related ion channels act as molecular sensors for distinct spices, yet also detect other sensory modalities including pain.2 The pioneer that triggered this avalanche of discoveries was the “capsaicin receptor”, now termed TRPV1 which stands for “transient receptor potential vanilloid 1” ion channel. Responsible for the piquancy of red pepper (Capsicum spp.), the vanilloid capsaicin in its pure form is one of the most painful chemicals we know. It was the Hungarian pharmacologist Nicolas Jancsó who in the middle of the 20th century first recognised that capsaicin acts specifically on nociceptive afferent neurons.3 The exploration of this unique pharmacological profile of capsaicin led, in 1997, to the identification of TRPV1 as the molecular sensor of capsaicin, selectively expressed by unmyelinated and some thinly myelinated primary afferent neurons.4
TRPV1: a new target for treatment of visceral pain in IBS?
What are the mechanisms whereby we sense spices, and what do they have to do with functional disorders of the gastrointestinal (GI) tract? Even one decade ago, nobody could envisage that a large family of closely related ion channels act as molecular sensors for distinct spices, yet also detect other sensory modalities including pain.2 The pioneer that triggered this avalanche of discoveries was the “capsaicin receptor”, now termed TRPV1 which stands for “transient receptor potential vanilloid 1” ion channel. Responsible for the piquancy of red pepper (Capsicum spp.), the vanilloid capsaicin in its pure form is one of the most painful chemicals we know. It was the Hungarian pharmacologist Nicolas Jancsó who in the middle of the 20th century first recognised that capsaicin acts specifically on nociceptive afferent neurons.3 The exploration of this unique pharmacological profile of capsaicin led, in 1997, to the identification of TRPV1 as the molecular sensor of capsaicin, selectively expressed by unmyelinated and some thinly myelinated primary afferent neurons.4
- 1 February 2008
- Published by Wolters Kluwer Health in Pain
- Vol. 134 (3) , 245-253
Deletion of the acid-sensing ion channel ASIC3 prevents gastritis-induced acid hyperresponsiveness of the stomach–brainstem axis
Urons, we examined whether knockout of the ASIC2 or ASIC3 gene modifies afferent signalling of a gastric acid insult in the normal and inflamed stomach. The stomach of conscious mice (C57BL/6) was challenged with intragastric HCl; two hours later the activation of neurons in the nucleus tractus solitarii (NTS) of the brainstem was visualized by c-Fos immunocytochemistry. Mild gastritis was induced by addition of iodoacetamide (0.1%) to the drinking water for 7 days. Exposure of the gastric mucosa to HCl (0.25 M) caused a 3-fold increase in the number of c-Fos-positive neurons in the NTS. This afferent input to the NTS remained unchanged by ASIC3 knockout, whereas ASIC2 knockout augmented the c-Fos response to gastric HCl challenge by 33% (P < 0.01). Pretreatment of wild-type mice with iodoacetamide induced mild gastritis, as revealed by increased myeloperoxidase activity, and enhanced the number of NTS neurons responding to gastric HCl challenge by 41% (P < 0.01). This gastric acid hyperresponsiveness was absent in ASIC3 knockout mice but fully preserved in ASIC2 knockout mice. The current data indicate that ASIC3 plays a major role in the acid hyperresponsiveness associated with experimental gastritis. In contrast, ASIC2 appears to dampen acid-evoked input from the stomach to the NTS....
- 1 February 2008
- Published by Wolters Kluwer Health in Pain
- Vol. 134 (3) , 245-253
Deletion of the acid-sensing ion channel ASIC3 prevents gastritis-induced acid hyperresponsiveness of the stomach–brainstem axis
Urons, we examined whether knockout of the ASIC2 or ASIC3 gene modifies afferent signalling of a gastric acid insult in the normal and inflamed stomach. The stomach of conscious mice (C57BL/6) was challenged with intragastric HCl; two hours later the activation of neurons in the nucleus tractus solitarii (NTS) of the brainstem was visualized by c-Fos immunocytochemistry. Mild gastritis was induced by addition of iodoacetamide (0.1%) to the drinking water for 7 days. Exposure of the gastric mucosa to HCl (0.25 M) caused a 3-fold increase in the number of c-Fos-positive neurons in the NTS. This afferent input to the NTS remained unchanged by ASIC3 knockout, whereas ASIC2 knockout augmented the c-Fos response to gastric HCl challenge by 33% (P < 0.01). Pretreatment of wild-type mice with iodoacetamide induced mild gastritis, as revealed by increased myeloperoxidase activity, and enhanced the number of NTS neurons responding to gastric HCl challenge by 41% (P < 0.01). This gastric acid hyperresponsiveness was absent in ASIC3 knockout mice but fully preserved in ASIC2 knockout mice. The current data indicate that ASIC3 plays a major role in the acid hyperresponsiveness associated with experimental gastritis. In contrast, ASIC2 appears to dampen acid-evoked input from the stomach to the NTS....
- 1 December 2007
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 7 (6) , 563-569
Role of visceral afferent neurons in mucosal inflammation and defense
- 1 December 2007
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 7 (6) , 563-569
Role of visceral afferent neurons in mucosal inflammation and defense
- 1 December 2007
- Published by Elsevier in Neuroscience
- Vol. 150 (3) , 522-536
Experimental gastritis in mice enhances anxiety in a gender-related manner
- 1 December 2007
- Published by Elsevier in Neuroscience
- Vol. 150 (3) , 522-536
Experimental gastritis in mice enhances anxiety in a gender-related manner
- Open Access
- 16 March 2007
- Published by Springer Nature in BMC Pharmacology
- Vol. 7 (1) , 5
The enantiomers of tramadol and its major metabolite inhibit peristalsis in the guinea pig small intestine via differential mechanisms
Inhibition of intestinal peristalsis is a major side effect of opioid analgesics. Although tramadol is an opioid-like analgesic, its effect on gut motility is little known. Therefore, the effect of (+)-tramadol, (-)-tramadol and the major metabolite O-desmethyltramadol on intestinal peristalsis in vitro and their mechanisms of action were examined. Distension-induced peristalsis was recorded in fluid-perfused segments of the guinea pig small intestine. The intraluminal peristaltic pressure threshold (PPT) was used to quantify the motor effects of extraserosally administered drugs. Racemic tramadol, its (+)- and (-)-enantiomers and the major metabolite O-desmethyltramadol (0.1 – 100 μM) concentration-dependently increased PPT until peristalsis was transiently or persistently abolished. The rank order of potency was (-)-tramadol < (+)-tramadol <O-desmethyltramadol. The peristaltic motor inhibition caused by (+)- and (-)-tramadol was markedly and that of O-desmethyltramadol nearly completely prevented by naloxone, but left unaltered by the 5-hydroxytryptamine receptor antagonists methysergide plus tropisetron. The adrenoceptor antagonists prazosin plus yohimbine reduced the effect of (+)- and (-)-tramadol but not that of O-desmethyltramadol. The results show that the metabolite O-desmethyltramadol is more potent in inhibiting peristalsis than its parent compound. The action of all tramadol forms depends on opioid receptors, and that of (+)- and (-)-tramadol also involves adrenoceptors.
- 16 March 2007
- Published by Springer Nature in BMC Pharmacology
- Vol. 7 (1) , 5
Open AccessThe enantiomers of tramadol and its major metabolite inhibit peristalsis in the guinea pig small intestine via differential mechanisms
Inhibition of intestinal peristalsis is a major side effect of opioid analgesics. Although tramadol is an opioid-like analgesic, its effect on gut motility is little known. Therefore, the effect of (+)-tramadol, (-)-tramadol and the major metabolite O-desmethyltramadol on intestinal peristalsis in vitro and their mechanisms of action were examined. Distension-induced peristalsis was recorded in fluid-perfused segments of the guinea pig small intestine. The intraluminal peristaltic pressure threshold (PPT) was used to quantify the motor effects of extraserosally administered drugs. Racemic tramadol, its (+)- and (-)-enantiomers and the major metabolite O-desmethyltramadol (0.1 – 100 μM) concentration-dependently increased PPT until peristalsis was transiently or persistently abolished. The rank order of potency was (-)-tramadol < (+)-tramadol <O-desmethyltramadol. The peristaltic motor inhibition caused by (+)- and (-)-tramadol was markedly and that of O-desmethyltramadol nearly completely prevented by naloxone, but left unaltered by the 5-hydroxytryptamine receptor antagonists methysergide plus tropisetron. The adrenoceptor antagonists prazosin plus yohimbine reduced the effect of (+)- and (-)-tramadol but not that of O-desmethyltramadol. The results show that the metabolite O-desmethyltramadol is more potent in inhibiting peristalsis than its parent compound. The action of all tramadol forms depends on opioid receptors, and that of (+)- and (-)-tramadol also involves adrenoceptors.
- 1 March 2007
- Published by Elsevier in Neuroscience
- Vol. 145 (3) , 1108-1119
Increase in gastric acid–induced afferent input to the brainstem in mice with gastritis
- 1 March 2007
- Published by Elsevier in Neuroscience
- Vol. 145 (3) , 1108-1119
Increase in gastric acid–induced afferent input to the brainstem in mice with gastritis